<code id='6D296F8645'></code><style id='6D296F8645'></style>
    • <acronym id='6D296F8645'></acronym>
      <center id='6D296F8645'><center id='6D296F8645'><tfoot id='6D296F8645'></tfoot></center><abbr id='6D296F8645'><dir id='6D296F8645'><tfoot id='6D296F8645'></tfoot><noframes id='6D296F8645'>

    • <optgroup id='6D296F8645'><strike id='6D296F8645'><sup id='6D296F8645'></sup></strike><code id='6D296F8645'></code></optgroup>
        1. <b id='6D296F8645'><label id='6D296F8645'><select id='6D296F8645'><dt id='6D296F8645'><span id='6D296F8645'></span></dt></select></label></b><u id='6D296F8645'></u>
          <i id='6D296F8645'><strike id='6D296F8645'><tt id='6D296F8645'><pre id='6D296F8645'></pre></tt></strike></i>

          Home / hotspot / Wikipedia

          Wikipedia


          Wikipedia

          author:fashion    Page View:7
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In